论文部分内容阅读
充血性心力衰竭(congestive heart failure,CHF)是多种心血管疾病所致的一种临床综合征,其病理生理机制除交感神经系统(sympathetic nervous system,SNS)和肾素-血管紧张素-醛固酮系统(rennin-angiotensin-aldosterone system,RAAS)的激活外,细胞因子的激活和失衡也参与了CHF的发生发展过程。有研究证实,血管紧张素转换酶抑制剂(angiotensin convertingenzyme inhibiter,ACEI)不但能阻断SNS及RAAS的激活,还能调整细胞因子网络的失衡,逆转心室肥厚以及防止和延缓心室重构,有助于延缓、遏止CHF进展。本文总结了ACEI对CHF患者血清炎症细胞因子的干预作用的研究现状,探讨通过此途径治疗CHF的效果。
Congestive heart failure (CHF) is a clinical syndrome caused by a variety of cardiovascular diseases. Its pathophysiological mechanisms include the sympathetic nervous system (SNS) and renin-angiotensin-aldosterone System (rennin-angiotensin-aldosterone system, RAAS) activation, cytokine activation and imbalance are also involved in the occurrence and development of CHF. Studies have shown that angiotensin convertingenzyme inhibiter (ACEI) can not only block the activation of SNS and RAAS, but also can adjust the imbalance of cytokine network, reverse ventricular hypertrophy and prevent and delay ventricular remodeling, which is helpful To delay, stop the progress of CHF. This article summarizes the ACEI on CHF patients with serum inflammatory cytokines intervention research, and explore the effect of this approach to the treatment of CHF.